Hematologist Oncologist

SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI) and House Rx announced today that they have entered into a multi-year relationship that will integrate House Rx’s specialty medication dispensing model to operate and manage TOI’s clinic and pharmacy locations in multiple markets.House Rx provides clinics with specialized technology and services support from pharmacists and care coordinators. House Rx staff are integrated with the clinic to help patients start therapy as quickly as possible and drive adherence to treatment for better outcomes.TOI’s alignment with House Rx will expand patient access to oral specialty medications via TOI dispensary and pharmacy locations, and enhance in-office dispensary operations. The relationship will further enable TOI to provide convenient and affordable access to value-based therapies for patients as part of its comprehensive community-based care model.“By partnering with House Rx, we will accelerate the growth of our clinic-based oral drug dispensing capabilities and improve our ability to add pharmacy locations in California and Texas that will allow us to access patient populations that we previously could not serve,” said Dr. Daniel Virnich, CEO of The Oncology Institute. “We see this as one of the key drivers of our growth in upcoming years.”"With TOI, we have an innovative partner that cares deeply about delivering value-based care in the community setting," said Tesh Khullar, President and Co-Founder of House Rx. "By adopting our dispensing services and technology, TOI will strengthen their value-based care offering by ensuring more patients can access their specialty medications and receive the best possible outcomes from their treatments.”About The Oncology Institute, Inc.Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting

CERRITOS, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), has announced a strategic acquisition that aims to further consolidate the Greater Los Angeles market and establish the company as one of the largest value-based community oncology groups in the United States. The acquisition of Southland Radiation Oncology Network (SRON) will amplify TOI's radiation oncology market presence by five additional clinics across the eastern San Gabriel Valley and Inland Empire, providing TOI with a distinct advantage over local private practices and tertiary centers. The acquisition of SRON is an important milestone for TOI as they continue to expand their ability to provide complete population health for oncology care. It will enable broader coverage across the Los Angeles area, providing more access to life-saving care for those who may not be able to otherwise afford treatment or transportation. "We are thrilled to be taking this next step in our journey as we expand our radiation oncology practice locations, and look forward to serving the community with the highest quality of care," said Dan Virnich, MD, MBA, FACHE, President of The Oncology Institute. "This acquisition aligns with our strategic vision to be the leading value-based cancer care group in the U.S., and demonstrates our commitment to delivering comprehensive oncology solutions that will benefit our patients and the broader community." The acquisition of SRON will enable TOI to offer value-based radiation oncology care to more patients in the Greater Los Angeles area

Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, is thrilled to announce a non-exclusive partnership with The Oncology Institute (TOI), a premier provider of cutting-edge cancer care.